Yilmaz Ahmet
Ataturk University, Erzurum, Turkey.
Ann Agric Environ Med. 2020 Sep 11;27(3):481-484. doi: 10.26444/aaem/125394. Epub 2020 Jul 30.
Hepatitis A Virus (HAV), reportedly the most common cause of acute viral hepatitis in developing countries, infects millions of people worldwide each year. The aim of the study is to investigate the seropositivity of anti-hepatitis A virus (HAV) IgG and IgM in all age groups in Erzurum, and to determine the effect of various factors such as age, gender, climatic conditions and HAV vaccination (included in 2012 in the National Immunization Schedule on seroprevalence) on the seropositivity.
The serological results of 25,007 individuals referred to Erzurum Public Health Microbiology Laboratory between January 2015 - December 2018 were retrospectively reviewed to test for the presence of anti-HAV IgG and IgM. The patient ages were 0-93 years. Serum samples were analyzed by ELISA. S/CO values of ≥1.00 and >1.21 were considered positive for anti-HAV IgG and IgM, respectively; results below this value were considered negative.
Anti-HAV IgG and IgM seropositivities were 87.3% and 0.2%, respectively. Anti-HAV IgG prevalence - 88.5% and 86.4%, anti-HAV IgM positivity - 0.1% and 0.3% in men and women. Anti-HAV IgG seroprevalence - 87%, 73.2%, 58.7%, 75.2%, 86.1%, 89.8%, 96.1%, 99.1%, 99.1% and 99.3%, respectively, at 0-4, 5-9 10-14, 15-19, 20-24, 25-29, 30-39, 40-49, 50-59 and >60 age groups. Anti-HAV IgM seropositivity - 0, 0.1%, 0.7%, 0.7%, 0.3%, 0, 0.1%, 0.2%, 0.1%, and 0.2%, respectively, in the same age groups. Anti-HAV IgM positivity was the highest in November - 36(0.97%.
In Erzurum, anti-HAV IgG prevalence is tremendously high, whereas prevalence of anti-HAV IgM is exceptionally low, especially in the paediatric age group. Therefore, HAV vaccine is provided free of charge in Turkey, including Erzurum, since 2012.
据报道，甲型肝炎病毒（HAV）是发展中国家急性病毒性肝炎最常见的病因，每年全球有数百万人感染。本研究的目的是调查埃尔祖鲁姆所有年龄组中抗甲型肝炎病毒（HAV）IgG和IgM的血清阳性率，并确定年龄、性别、气候条件和HAV疫苗接种（2012年纳入国家免疫规划）等各种因素对血清阳性率的影响。
回顾性分析了2015年1月至2018年12月期间转诊至埃尔祖鲁姆公共卫生微生物实验室的25007名个体的血清学结果，以检测抗HAV IgG和IgM的存在。患者年龄为0至93岁。血清样本通过酶联免疫吸附测定（ELISA）进行分析。抗HAV IgG和IgM的S/CO值分别≥1.00和>1.21被视为阳性；低于此值的结果被视为阴性。
抗HAV IgG和IgM的血清阳性率分别为87.3%和0.2%。男性和女性的抗HAV IgG患病率分别为88.5%和86.4%，抗HAV IgM阳性率分别为0.1%和0.3%。0至4、5至9、10至14、15至19、20至24、25至29、30至39、40至49、50至59和>60岁年龄组的抗HAV IgG血清患病率分别为87%、73.2%、58.7%、75.2%、86.1%、89.8%、96.1%、99.1%、99.1%和99.3%。同一年龄组的抗HAV IgM血清阳性率分别为0、0.1%、0.7%、0.7%、0.3%、0、0.1%、0.2%、0.1%和0.2%。抗HAV IgM阳性率在11月最高，为36例（0.97%）。
在埃尔祖鲁姆，抗HAV IgG患病率极高，而抗HAV IgM患病率极低，尤其是在儿童年龄组。因此，自
